FDA Approval Draws Higher Price Target For Bristol-Myers
Goldman Sachs maintains buy rating after agency rubber-stamps melanoma treatment.
More: continued here
Goldman Sachs maintains buy rating after agency rubber-stamps melanoma treatment.
More: continued here